• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pfizer talking with CROs to fill R&D hub

Pfizer talking with CROs to fill R&D hub

March 16, 2011
CenterWatch Staff

A U.K. task force—assembled to salvage as many R&D jobs at Sandwich as it can before Pfizer completes its planned exit—has confirmed that the pharma giant is in discussions with CROs that may step in to hire some of the 2,400 workers being let go, according to Fierce Biotech.

Pfizer hopes the CROs will keep the research hub in operation, studying drugs for the pharma giant as well as others. The task force will be rooting for a slate of tax and planning breaks for companies moving into the research hub, which the group would like to turn into an economic enterprise zone.  Pfizer has also signed confidentiality agreements with 10 companies that have signaled an interest in picking up where Pfizer leaves off.

"Our report focuses on the opportunities presented by the world-class skills and facilities built by Pfizer over the last 60 years," said one of the task force leaders. "Combined, they offer a unique asset on which to build a new model of high-tech growth and employment, which would be of importance not only to Kent, but to the country."

Pfizer has made it clear that it plans to use more CRO talent to shoulder development work. It's been following in the footsteps of Eli Lilly, Sanofi-aventis, GlaxoSmithKline and others that have turned facilities over to CROs as they downsize in-house research operations.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing